Member Info for RayPointer

So a marginal improvement does not tell us anything on a sample size of 25.
But the bigger the improvement, the more statistically significant it becomes.

You make a good point Bermuda.
25 is not an ideal number of patients.
But if the number of complete responses is much higher than 5 then it starts to become more statistically significant.
We just have to wait and see how the data pans out.

I really don't know but would re-formulating SCIB1 as SCIB1 plus (already done in mouse experiments ) count as evergreening as defined in the article I posted.
Would nano-particle delivery likewise fall under evergreening?

I can see your point of view.
I am far from an expert on laws surrounding patents.
But this may be of interest

https://www.upcounsel.com/how-long-does-a-drug-patent-last

Big pharma will play every trick in the book to try to extend the normal 20 year patent period.

How can you write off SCIB1 Knowlesi?
Understand that I am not advocating buy and not ramping.
I am just interested in why you think that SCIB1 is now written off. It would be good to hear both sides of the argument.
I will start if off by stating my point of view.
There is an obvious synergy between SCIB1 and Keytruda that promises much but until a trial is run we won't know if that promise becomes reality.

I was intrigued what a rambutan-like nano-particle looked like

https://en.wikipedia.org/wiki/Rambutan

Of course, the nano-particle is much, much, much smaller and I wouldn't recommend eating them.

Thanks Inan

https://www.ncbi.nlm.nih.gov/pubmed/29151352

"For silica nanoparticles with rambutan-, raspberry-, and flower-like morphologies composed of spike-, hemisphere-, and bowl-type subunit nanotopographies, respectively, the rambutan-like nanoparticles with spiky surfaces demonstrate the highest plasmid DNA binding capability and transfection efficacy of 88%, higher than those reported for silica-based nanovectors."

"transfection efficacy of 88%" - I'm guessing that is very high.
It looks like spiky surfaces on the nano-particles help the transfection. Makes sense to me when you are trying to pierce a cell membrane.

One aspect of nano-delivery that interests me is targeted delivery.

Here's an article that describes one type of targeting

https://www.spandidos-publications.com/ijo/52/2/389

"In order to improve the specificity of nanocarriers, targeting ligands may be attached to their surface via a PEG spacer arm. The targeting ligands, which are attached to the distal end of the spacer arm on the surface of nanocarriers, facilitate access of the carrier to the targeted site of interaction (3). Delivery of nanoparticle involving the use of peripherally-conjugated targeting moieties is known as active targeting. Active targeting is a promising tool for the treatment of cancer due to its ability to increase therapeutic effectiveness and reduce potential side effects. "

So nano-delivery does not open up the target cells in the same way that Trigrid does. However, by attaching ligands to the nano-particle it may be more efficient in reaching the correct target. This is, I believe, why it can match and possibly surpass the efficiency of Trigrid.
In addition it protects the vaccine from degradation.

Last AGM Lindy gave an exciting talk about MODi2. I wasn't there but you could tell from Steve's recording just how excited she was about it.

To me, Lindy's talk is always the highlight of the AGM.
This year's subject ?
Gylcans?
More development of Modi2?
More on combination of Modi1 and Modi2?
Details of the nano-delivery chosen for SCIB2?

If agree, get it done ASAP.
CH will be there having faced Archer in 3 test matches so they may have to wheel him in or he may have to dial in from his hospital bed.

I'll have some of that coffee Ruck.

Yes, when you see a list of all the activities carried out and those planned for the next 12 months, it is really impressive for such a small company.
Interesting comments from Inan as well about the Biontech TCR collaboration and the possible direction it is taking. Research time for me I think.

Although I with you on CH's performance back in April I think today's news is good.
We are finally in the clinic - at least I think we are!

Plus an update on Modi1 timescales

CH has volunteered to be the new Aussie number 4.

I didn't know you could get clap on the back LOL

"Having considered the ethical issues related to patients awaiting enrolment into the UK sites, Scancell has decided to withdraw its IND application in the US to allow the UK arm of the trial to proceed."

It sounds as though the clinicians already have patients lined up.

"In order to initiate patient recruitment in the UK under the Investigational New Drug (IND) application submitted to the Agency, prior approval of the IND is required. Having considered the ethical issues related to patients awaiting enrolment into the UK sites, Scancell has decided to withdraw its IND application in the US to allow the UK arm of the trial to proceed."

This was the information that CH missed out from his previous RNS. The UK arm of the trial starting was conditional on the FDA IND being approved.
Really glad that the UK trial can now go ahead but at the same time CH has gone down in my estimation.

I think I am right in saying that Scancell were the first to use Trigrid for delivering a cancer vaccine.

So the probable sequence was pre SCIB1 trial

a) LD is interested in how to improve SCIB1 delivery
b) Hears about Trigrid, likes the science so decides to give it a try
c) It proves highly effective

A similar approach to the inclusion of Amplivant for Moditope.
2 examples of LD's knowledge of recent advances and how they could be used to improve her vaccines.

"Richard was formerly in senior management at Astra where he ran international clinical trials on Astra’s gastrointestinal and cardiovascular products including omeprazole before becoming Director of international Product Marketing."

http://www.scancell.co.uk/company/board-of-directors
https://www.linkedin.com/in/richard-goodfellow-60ab1511/?originalSubdomain=uk

IMO, it is probable that AZ is one of the companies Scancell has had talks with and with an NDA in place. Simply because of Richard's previous senior position in Astra.
So it is entirely possible that Richard was the first person to make AZ aware of Ichor and Trigrid.

Looks like you have escaped detention and lines today C7 LOL